10,471 Shares in Gilead Sciences, Inc. $GILD Acquired by Winnow Wealth LLC

Winnow Wealth LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 10,471 shares of the biopharmaceutical company’s stock, valued at approximately $1,162,000. Gilead Sciences comprises approximately 0.9% of Winnow Wealth LLC’s investment portfolio, making the stock its 25th largest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bryn Mawr Trust Advisors LLC lifted its stake in shares of Gilead Sciences by 20.2% in the 3rd quarter. Bryn Mawr Trust Advisors LLC now owns 3,461 shares of the biopharmaceutical company’s stock valued at $384,000 after purchasing an additional 581 shares during the period. Cornerstone Wealth Management LLC increased its holdings in Gilead Sciences by 1.5% in the third quarter. Cornerstone Wealth Management LLC now owns 7,479 shares of the biopharmaceutical company’s stock worth $830,000 after purchasing an additional 113 shares in the last quarter. Significant Wealth Partners LLC lifted its stake in Gilead Sciences by 12.4% in the third quarter. Significant Wealth Partners LLC now owns 6,474 shares of the biopharmaceutical company’s stock valued at $719,000 after buying an additional 713 shares during the period. AlphaQuest LLC boosted its holdings in shares of Gilead Sciences by 10.9% during the 3rd quarter. AlphaQuest LLC now owns 11,143 shares of the biopharmaceutical company’s stock worth $1,237,000 after buying an additional 1,096 shares in the last quarter. Finally, Argent Advisors Inc. boosted its holdings in shares of Gilead Sciences by 7.4% during the 3rd quarter. Argent Advisors Inc. now owns 11,622 shares of the biopharmaceutical company’s stock worth $1,290,000 after buying an additional 798 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the sale, the chief financial officer directly owned 150,503 shares of the company’s stock, valued at $18,709,027.93. This represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Kelly A. Kramer sold 2,805 shares of the stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the transaction, the director owned 1,339 shares of the company’s stock, valued at $170,186.90. This represents a 67.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 257,397 shares of company stock worth $33,385,512 in the last quarter. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Gilead Sciences Stock Up 1.7%

GILD opened at $141.95 on Friday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $142.20. The company’s 50-day moving average price is $125.36 and its two-hundred day moving average price is $119.59. The stock has a market cap of $176.11 billion, a price-to-earnings ratio of 22.01, a PEG ratio of 0.73 and a beta of 0.33. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter in the prior year, the business earned $2.02 earnings per share. Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on GILD shares. Argus increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Truist Financial upped their price target on Gilead Sciences from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Needham & Company LLC boosted their price objective on Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Finally, Citigroup upped their target price on Gilead Sciences from $140.00 to $156.00 and gave the stock a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $136.36.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.